Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sonoma Pharmaceuticals (SNOA) EPS (Weighted Average and Diluted) (2016 - 2025)

Sonoma Pharmaceuticals has reported EPS (Weighted Average and Diluted) over the past 12 years, most recently at -$0.48 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 23.81% year-over-year to -$0.48; the TTM value through Dec 2025 reached -$1.95, up 20.41%, while the annual FY2025 figure was -$2.79, 73.75% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.48 at Sonoma Pharmaceuticals, down from -$0.32 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $0.11 in Q1 2024 and troughed at -$5.75 in Q3 2023.
  • A 5-year average of -$0.81 and a median of -$0.44 in 2025 define the central range for EPS (Weighted Average and Diluted).
  • Biggest five-year swings in EPS (Weighted Average and Diluted): crashed 1642.42% in 2023 and later surged 128.54% in 2024.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.31 in 2021, then tumbled by 100.0% to -$0.62 in 2022, then tumbled by 156.45% to -$1.59 in 2023, then surged by 60.38% to -$0.63 in 2024, then rose by 23.81% to -$0.48 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for SNOA at -$0.48 in Q4 2025, -$0.32 in Q3 2025, and -$0.76 in Q2 2025.